Comparative Pharmacology
Head-to-head clinical analysis: MELFIAT versus MELFIAT 105.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MELFIAT versus MELFIAT 105.
MELFIAT vs MELFIAT-105
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Melfiat is a sympathomimetic amine that acts as an anorectic agent. Its mechanism of action involves stimulating the release of norepinephrine and dopamine from presynaptic nerve terminals in the hypothalamus, leading to suppression of appetite.
Selective serotonin reuptake inhibitor (SSRI); potentiates serotonergic activity in the CNS by inhibiting reuptake of serotonin at the presynaptic neuronal membrane.
1 to 2 tablets (75 to 150 mg mazindol) orally once daily with breakfast.
105 mg orally once daily in the morning.
None Documented
None Documented
Terminal elimination half-life is approximately 10-12 hours in healthy adults; may be prolonged in renal impairment.
The terminal elimination half-life is approximately 4-6 hours, supporting twice-daily dosing in clinical practice.
Primarily renal (70-80% as unchanged drug and metabolites), with ~20% eliminated via bile into feces.
Approximately 90% of an administered dose is excreted renally as unchanged drug and metabolites, with the remainder eliminated via biliary/fecal routes.
Category C
Category C
Anorexiant
Anorexiant